Albemarle Corporation (NYSE:ALB) – Analysts at Oppenheimer Holdings boosted their FY2020 earnings per share estimates for shares of Albemarle Corporation in a research note issued on Monday. Oppenheimer Holdings analyst C. Rusch now anticipates that the specialty chemicals company will post earnings of $6.12 per share for the year, up from their prior estimate of $5.89. Oppenheimer Holdings currently has a “Outperform” rating and a $157.00 target price on the stock. Oppenheimer Holdings also issued estimates for Albemarle Corporation’s FY2021 earnings at $6.88 EPS.

Albemarle Corporation (NYSE:ALB) last issued its quarterly earnings results on Monday, August 7th. The specialty chemicals company reported $1.13 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.02. The firm had revenue of $737.25 million during the quarter, compared to analysts’ expectations of $735.50 million. Albemarle Corporation had a net margin of 31.49% and a return on equity of 11.59%. Albemarle Corporation’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.93 EPS.

TRADEMARK VIOLATION NOTICE: “FY2020 Earnings Estimate for Albemarle Corporation Issued By Oppenheimer Holdings (ALB)” was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/17/fy2020-earnings-estimate-for-albemarle-corporation-issued-by-oppenheimer-holdings-alb.html.

ALB has been the subject of several other research reports. KeyCorp reissued a “buy” rating and set a $125.00 price target on shares of Albemarle Corporation in a report on Sunday, September 3rd. Zacks Investment Research downgraded shares of Albemarle Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Instinet boosted their price target on shares of Albemarle Corporation from $134.00 to $146.00 and gave the company a “buy” rating in a report on Monday, September 18th. Nomura boosted their price target on shares of Albemarle Corporation from $146.00 to $154.00 and gave the company a “buy” rating in a report on Tuesday, October 10th. Finally, Aegis reissued a “buy” rating on shares of Albemarle Corporation in a report on Friday, July 7th. Eight analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $122.95.

Shares of Albemarle Corporation (NYSE ALB) traded down 0.67% during mid-day trading on Tuesday, reaching $139.22. 716,282 shares of the company were exchanged. The company’s 50-day moving average is $128.91 and its 200 day moving average is $115.43. Albemarle Corporation has a 12 month low of $76.32 and a 12 month high of $140.70. The firm has a market capitalization of $15.38 billion, a price-to-earnings ratio of 17.81 and a beta of 1.66.

A number of institutional investors have recently modified their holdings of ALB. Stifel Financial Corp raised its position in Albemarle Corporation by 4.7% in the first quarter. Stifel Financial Corp now owns 7,437 shares of the specialty chemicals company’s stock worth $793,000 after acquiring an additional 333 shares in the last quarter. AXA bought a new stake in Albemarle Corporation in the first quarter worth about $359,000. Thrivent Financial For Lutherans raised its position in Albemarle Corporation by 5.3% in the first quarter. Thrivent Financial For Lutherans now owns 4,150 shares of the specialty chemicals company’s stock worth $438,000 after acquiring an additional 210 shares in the last quarter. Global X Management Co. LLC raised its position in Albemarle Corporation by 23.8% in the first quarter. Global X Management Co. LLC now owns 78,843 shares of the specialty chemicals company’s stock worth $8,329,000 after acquiring an additional 15,142 shares in the last quarter. Finally, MARSHALL WACE ASIA Ltd bought a new stake in Albemarle Corporation in the first quarter worth about $3,142,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

In other Albemarle Corporation news, EVP Matthew Juneau sold 5,397 shares of the business’s stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $115.77, for a total value of $624,810.69. Following the sale, the executive vice president now directly owns 360 shares in the company, valued at $41,677.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Karen G. Narwold sold 11,500 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $115.95, for a total transaction of $1,333,425.00. Following the completion of the sale, the executive vice president now owns 36,620 shares in the company, valued at $4,246,089. The disclosure for this sale can be found here. Corporate insiders own 0.74% of the company’s stock.

Albemarle Corporation Company Profile

Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.

Earnings History and Estimates for Albemarle Corporation (NYSE:ALB)

Receive News & Ratings for Albemarle Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle Corporation and related companies with MarketBeat.com's FREE daily email newsletter.